Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Nu-Tek BioSciences Showcases Animal-Free Ingredients Driving Pharma Innovation at CPhI Global 2025

    October 2, 2025

    Semtech Launches 1.6T Multimode Optical Solutions for AI Data Centres

    October 1, 2025

    US Government Shutdown 2025: Why It’s Happening and Who’s Impacted

    September 30, 2025
    Facebook X (Twitter) Instagram LinkedIn
    • About Us
    • Press Release
    Thursday, October 2
    Facebook X (Twitter) LinkedIn Instagram
    Business Leaders Review: Best Business Magazine and News OnlineBusiness Leaders Review: Best Business Magazine and News Online
    • Home
    • Magazines
    • Featured Leaders
    • Technology
      • Big Data
      • Artificial Intelligence
      • Robotics
      • Cloud
      • Cyber Security
      • Storage
      • IoT
      • Blockchain
      • Data Analytics
    • Industry
      • Banking & Finance
      • Construction
      • Digital Marketing
      • Economy
      • Education
      • EV Industry
      • Food & Beverage
      • Healthcare
      • Legal
      • Manufacturing
      • Mining & Metals
      • Pharmaceutical
    • Testimonials
    • Events
    • Blogs
    • Awards
    • Our Clients
    Business Leaders Review: Best Business Magazine and News OnlineBusiness Leaders Review: Best Business Magazine and News Online
    Home » Eli Lilly: Sleep Apnea Reduced in Last Stage Trials, Zepbound Drug tested
    Industry News

    Eli Lilly: Sleep Apnea Reduced in Last Stage Trials, Zepbound Drug tested

    By Business Leaders ReviewApril 18, 2024
    Eli Lilly: Sleep Apnea Reduced in Last Stage Trials, Zepbound Drug tested

    Eli Lilly’s weight-loss medicine Zepbound has been shown to improve obstructive sleep apnea in obese individuals, according to a press statement issued Wednesday.

    The medication reduced the frequency of irregular breathing episodes by up to 63% across both groups.

    The study findings add to a growing body of clinical data indicating that popular GLP-1 medications like as Lilly’s Zepbound and Novo Nordisk’s (NOVOb.CO), open new tab Wegovy, offer medical advantages beyond diabetes and weight reduction.

    Last month, the US Food and Drug Administration authorized Wegovy to reduce the risk of stroke and heart attack in overweight or obese people who do not have diabetes.

    Early trading saw shares of the Indianapolis-based pharmaceutical rise 1.6% to $758.64. Lilly’s stock has increased 26% since January.

    The National Council on Aging estimates that around 39 million persons in the United States suffer with obstructive sleep apnea.

    It happens when a person’s upper airway becomes clogged while sleeping, preventing airflow throughout the night, according to the National Heart, Lung, and Blood Institute. Obesity, which can restrict the airway, heightens a person’s risk.

    If left untreated, sleep apnea can cause cardiac arrhythmias, heart failure, and even death.

    Wegovy was proven to lessen the risk of heart disease, therefore Medicare said last month that it will pay for medication for some patients.

    Lilly said it hopes to offer further information about the study results at the American Diabetes Association meeting in June.

    It intends to submit the findings to the Food and Drug Administration around mid-year.

    Related Posts

    Nu-Tek BioSciences Showcases Animal-Free Ingredients Driving Pharma Innovation at CPhI Global 2025

    October 2, 2025

    Semtech Launches 1.6T Multimode Optical Solutions for AI Data Centres

    October 1, 2025

    US Government Shutdown 2025: Why It’s Happening and Who’s Impacted

    September 30, 2025

    Trump’s Import Probe Triggers Fall in U.S. Medtech Stocks

    September 27, 2025

    Teleport Enhances Identity Security with AI-Powered Session Summaries

    September 27, 2025

    Next-Generation Humanoid Robot Stuns the World With a Perfect Moonwalk

    September 25, 2025
    Top Posts

    Nu-Tek BioSciences Showcases Animal-Free Ingredients Driving Pharma Innovation at CPhI Global 2025

    October 2, 2025

    Semtech Launches 1.6T Multimode Optical Solutions for AI Data Centres

    October 1, 2025

    US Government Shutdown 2025: Why It’s Happening and Who’s Impacted

    September 30, 2025
    Don't Miss

    Nu-Tek BioSciences Showcases Animal-Free Ingredients Driving Pharma Innovation at CPhI Global 2025

    October 2, 2025

    Key Highlights Nu-Tek BioSciences, a leader in animal-free peptones and specialty yeast extracts, has announced…

    Semtech Launches 1.6T Multimode Optical Solutions for AI Data Centres

    October 1, 2025

    US Government Shutdown 2025: Why It’s Happening and Who’s Impacted

    September 30, 2025

    AI in the Workplace: How AI and Demographic Shifts Are Redefining the Future of Work

    September 27, 2025
    Stay In Touch
    • Facebook
    • Twitter
    • Instagram
    • LinkedIn
    About Us
    About Us

    Business Leaders Review is a global print and digital monthly and yearly magazine, which provides a platform to showcase business/tech leaders and their company’s profile from various sectors. Our aim is to publish the c-suite leaders stories.

    We are helping the leaders & readers to showcase their ideas and innovations to the business and tech world in this current market situation along with their awards and achievements. Doing so we hope to leverage thousands of businesses and personnel around the globe.

    Most Popular

    Nu-Tek BioSciences Showcases Animal-Free Ingredients Driving Pharma Innovation at CPhI Global 2025

    Semtech Launches 1.6T Multimode Optical Solutions for AI Data Centres

    US Government Shutdown 2025: Why It’s Happening and Who’s Impacted

    Latest Magazines
    Facebook X (Twitter) LinkedIn Instagram
    • Home
    • Our Clients
    • TECHNLOGY NEWS
    • Industry News
    • Contact Us
    • Privacy Policy
    • Reprints and Permissions
    © 2021-2025 Business Leaders Review LLC | All Rights Reserved | Empowering Communication Globally

    Type above and press Enter to search. Press Esc to cancel.